Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
Engage & Connect: A novel, neuroscience-informed streamlined psychotherapy for postpartum depression
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 18, 2022
A Digital Intervention for Post-Stroke Depression and Executive Dysfunction
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 14, 2022
SSRI Impact On Sperm Quality: A Randomized Placebo Controlled Trial
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 11, 2022
Pharmacokinetic Evaluation of Serum Testosterone Concentrations After Administration of Clomiphene Citrate
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 11, 2022
Tissue Collection for Drug Screening and Bioanalysis
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 14, 2022
A Phase I/Ib Study of BP1002 (a Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML)
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 13, 2022
Phase IA Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich’s Ataxia
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 13, 2023
A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-Tumor Activity Study of IMM-1-104, A Novel Oral Dual MEK1/2 Inhibitor in Participants with Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 16, 2023
Efficacy of Targeted App-Based Cognitive Behavioral Therapy for Anxiety and Depression
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 2, 2023
Whole-Food Plant-Based Diet (WFPBD) to Control Weight and Metabo-Inflammation in Overweight/Obese Men with Prostate Cancer Receiving Androgen Deprivation Therapy (ADT): A Multi-Center Randomized Control Trial
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 16, 2023